Biotechnology - Rare diseases, Novartis


Current filters:

Rare diseasesNovartis

Popular Filters

News briefs: Auxilium/Pfizer accord; Novartis Signifor and RLX030 developments


US specialty drugmaker Auxilium Pharmaceuticals' (Nasdaq: AUXL) shares fell 7.2% to $18.60 at close of…

Auxilium PharmaceuticalsBiotechnologyCardio-vascularLicensingNovartisOncologyPfizerPharmaceuticalRare diseasesResearchRLX030SigniforXiaflexXiapex

FDA approves Incytes’ Jakafi, first drug to treat MF; advisory panel backs Pfizer’s Prevnar 13 for adults


USA-based Incyte (Nasdaq: INCY) saw its shares rise 10% to$13.90 on the news that the Food and Drug Administration…

BiotechnologyIncyteJakafiNorth AmericaNovartisPfizerPharmaceuticalPrevnarRare diseasesRegulationruxolitinibVaccines

Back to top